Amylin, India's Biocon Join Hands For Peptide-Based Diabetes Compound
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Biocon, India's largest biotech with products ranging from insulins to monoclonal antibodies and Amylin - developers of insulin injection Byetta (exanetide) - have agreed to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes